Emily L Hoskins, Eric Samorodnitsky, Michele R Wing, Julie W Reeser, Julia F Hopkins, Karthikeyan Murugesan, Zheng Kuang, Raven Vella, Leah Stein, Zachary Risch, Lianbo Yu, Serifat Adebola, Anoosha Paruchuri, John Carpten, Jad Chahoud, Stephen Edge, Jill Kolesar, Martin McCarter, Kenneth G Nepple, Matthew Reilley, Courtney Scaife, Abhishek Tripathi, Nancy Single, Richard S P Huang, Lee A Albacker, Sameek Roychowdhury
PURPOSE: Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability, tumor mutational burden, and programmed death ligand-1 (PD-L1) immunohistochemistry. Structural variations (SVs) in PD-L1 ( CD274 ) and PD-L2 ( PDCD1LG2 ) have been observed in cancer, but the comprehensive landscape is unknown. Here, we describe the genomic landscape of PD-L1 and PD-L2 SVs, their potential impact on the tumor microenvironment, and evidence that patients with these alterations can benefit from immunotherapy...
January 2023: JCO Precision Oncology